CN117642161A - 与阿扎胞苷联合用于治疗骨髓增生异常综合征的维奈托克给药方案 - Google Patents
与阿扎胞苷联合用于治疗骨髓增生异常综合征的维奈托克给药方案 Download PDFInfo
- Publication number
- CN117642161A CN117642161A CN202280048997.0A CN202280048997A CN117642161A CN 117642161 A CN117642161 A CN 117642161A CN 202280048997 A CN202280048997 A CN 202280048997A CN 117642161 A CN117642161 A CN 117642161A
- Authority
- CN
- China
- Prior art keywords
- count
- baseline
- human subject
- equal
- white blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Dermatology (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163201749P | 2021-05-11 | 2021-05-11 | |
| US63/201749 | 2021-05-11 | ||
| PCT/US2022/028429 WO2022240786A1 (en) | 2021-05-11 | 2022-05-10 | Venetoclax dosing regimens for use in treating myelodysplastic syndromes in combination with azacitidine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117642161A true CN117642161A (zh) | 2024-03-01 |
Family
ID=84028499
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202280048997.0A Withdrawn CN117642161A (zh) | 2021-05-11 | 2022-05-10 | 与阿扎胞苷联合用于治疗骨髓增生异常综合征的维奈托克给药方案 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220378811A1 (enExample) |
| EP (1) | EP4337183A4 (enExample) |
| JP (1) | JP2024517318A (enExample) |
| KR (1) | KR20240006659A (enExample) |
| CN (1) | CN117642161A (enExample) |
| AU (1) | AU2022273023A1 (enExample) |
| BR (1) | BR112023023677A2 (enExample) |
| CA (1) | CA3219760A1 (enExample) |
| IL (1) | IL308321A (enExample) |
| MX (1) | MX2023013364A (enExample) |
| WO (1) | WO2022240786A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220315555A1 (en) | 2009-05-26 | 2022-10-06 | Abbvie Inc. | Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3258941A4 (en) * | 2015-02-17 | 2018-09-26 | Cantex Pharmaceuticals, Inc. | Treatment of cancers and hematopoietic stem cell disorders privileged by cxcl12-cxcr4 interaction |
| JP7585231B2 (ja) * | 2019-04-29 | 2024-11-18 | イミュノジェン， インコーポレイテッド | 抗ｃｄ１２３免疫複合体を含む治療的組み合わせ |
| WO2020257671A1 (en) * | 2019-06-20 | 2020-12-24 | Celgene Corporation | Azacitidine in combination with venetoclax, gilteritinib, midostaurin or other compounds for treating leukemia or myelodysplastic syndrome |
| WO2021037933A1 (en) * | 2019-08-28 | 2021-03-04 | Astrazeneca Ab | Combination of azd2811 nanoparticles, 5-azacitidine and venetoclax for use in the treatment of cancer |
| PH12022550835A1 (en) * | 2019-10-18 | 2023-07-03 | Forty Seven Inc | Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia |
-
2022
- 2022-05-10 BR BR112023023677A patent/BR112023023677A2/pt unknown
- 2022-05-10 US US17/741,359 patent/US20220378811A1/en not_active Abandoned
- 2022-05-10 IL IL308321A patent/IL308321A/en unknown
- 2022-05-10 CA CA3219760A patent/CA3219760A1/en active Pending
- 2022-05-10 JP JP2023569885A patent/JP2024517318A/ja active Pending
- 2022-05-10 AU AU2022273023A patent/AU2022273023A1/en not_active Abandoned
- 2022-05-10 WO PCT/US2022/028429 patent/WO2022240786A1/en not_active Ceased
- 2022-05-10 CN CN202280048997.0A patent/CN117642161A/zh not_active Withdrawn
- 2022-05-10 MX MX2023013364A patent/MX2023013364A/es unknown
- 2022-05-10 EP EP22808145.1A patent/EP4337183A4/en not_active Withdrawn
- 2022-05-10 KR KR1020237042682A patent/KR20240006659A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL308321A (en) | 2024-01-01 |
| CA3219760A1 (en) | 2022-11-17 |
| JP2024517318A (ja) | 2024-04-19 |
| AU2022273023A1 (en) | 2023-11-23 |
| US20220378811A1 (en) | 2022-12-01 |
| BR112023023677A2 (pt) | 2024-02-20 |
| KR20240006659A (ko) | 2024-01-15 |
| EP4337183A1 (en) | 2024-03-20 |
| WO2022240786A1 (en) | 2022-11-17 |
| MX2023013364A (es) | 2023-11-27 |
| EP4337183A4 (en) | 2025-04-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6726252B2 (ja) | 骨髄抑制の処置 | |
| Choy et al. | Therapeutic benefit of blocking interleukin‐6 activity with an anti–interleukin‐6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double‐blind, placebo‐controlled, dose‐escalation trial | |
| CN108883109A (zh) | 用于治疗急性髓性白血病的联合疗法 | |
| Robak et al. | Rituximab combined with cladribine or with cladribine and cyclophosphamide in heavily pretreated patients with indolent lymphoproliferative disorders and mantle cell lymphoma | |
| CN117651556A (zh) | 与cyp3a抑制剂和阿扎胞苷联合治疗骨髓增生异常综合征的维奈托克给药方案 | |
| Zhang et al. | Therapeutic potential of low‐dose IL‐2 in immune thrombocytopenia: an analysis of 3 cases | |
| Hansen‐Abeck et al. | Pegylated interferon‐α2a in cutaneous T‐cell lymphoma–a multicenter retrospective data analysis with 70 patients | |
| TWI899057B (zh) | 接受造血幹細胞移植的患者之血液惡性腫瘤的復發抑制劑 | |
| US20220378811A1 (en) | Venetoclax dosing regimens for use in treating myelodysplastic syndromes in combination with azacitidine | |
| WO2021037933A1 (en) | Combination of azd2811 nanoparticles, 5-azacitidine and venetoclax for use in the treatment of cancer | |
| Dallorso et al. | Clinical benefits of granulocyte colony-stimulating factor therapy after hematopoietic stem cell transplant in children: results of a prospective randomized trial | |
| Göçer et al. | Safety and efficacy analysis of ibrutinib in 32 patients with CLL and various B-cell lymphomas: real-world data from a single-center study in Turkey | |
| HK40106739A (en) | Venetoclax dosing regimens for use in treating myelodysplastic syndromes in combination with azacitidine | |
| HK40106881A (en) | Venetoclax dosing regimens for use in treating myelodysplastic syndromes in combination with a cyp3a inhibitor and azacitidine | |
| Chang et al. | Rituximab and CHOP chemotherapy plus GM-CSF for previously untreated diffuse large B-cell lymphoma in the elderly: a Wisconsin oncology network study | |
| WO2023234933A1 (en) | Dosing for treatment with anti-cd20/anti-cd3 bispecific antibodies in elderly patients | |
| Lundin et al. | Phase II study of cyclophosphamide, interferon-a and betamethasone (CIB) as induction therapy for patients 6075 years of age with multiple myeloma stages II and III | |
| AU2018201697B2 (en) | Treatment of myelosuppression | |
| WO2025014827A1 (en) | Pralatrexate and cop combination for the treatment of patients with peripheral t cell lymphoma | |
| Göçer et al. | BLOOD RESEARCH | |
| WO2025122961A1 (en) | Methods for treating neutropenia | |
| WO2024211523A1 (en) | Dosing regimens for use in preventing relapse of acute myeloid leukemia following allogeneic hematopoietic stem cell transplantation with venetoclax in combination with azacitidine | |
| List | Management of myelodysplastic syndromes | |
| بسام فرنسيس متي et al. | Efficacy and Tolerance of Fludarabine and Cyclophosphamide (FC) Combination Regimen in Advance Stage of Chronic Lymphocytic Leukemia | |
| Stathopoulos et al. | Metastatic renal cancer and patient survival as a criterion of treatment response |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40106739 Country of ref document: HK |
|
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20240301 |
|
| WW01 | Invention patent application withdrawn after publication |